Sun eyes operational efficiencies to unlock value in ex-URL generics
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries sees significant opportunities to unlock value and improve the performance of URL Pharma's generics business acquired from Takeda late last year.